Equities

Kalbe Farma Tbk PT

Kalbe Farma Tbk PT

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (IDR)1,475.00
  • Today's Change15.00 / 1.03%
  • Shares traded30.18m
  • 1 Year change-31.40%
  • Beta0.4402
Data delayed at least 10 minutes, as of Mar 28 2024 09:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

PT Kalbe Farma Tbk is an Indonesia-based company, which is engaged in the development, manufacturing and trading of pharmaceutical products including human medicines and consumer health products. Its business divisions include Prescription Pharmaceutical, Consumer Health Division, Nutritionals, and Distribution and Logistic divisions. The Prescription Pharmaceuticals division provides a range of products for all groups, from unbranded generic drugs for the mass-market segment, to branded generics and licensed drugs. The Consumer Health division's product portfolio spans from over the counter (OTC) drugs and energy drinks to a selection of ready-to-drink healthy beverage products. The Nutritional division manages a range of nutritional products, comprising of powdered milk products for all age segments. It also offers a selection of non-milk nutritional products. The Distribution and Logistics Division operates the distribution coverage for pharmaceuticals products in Indonesia.

  • Revenue in IDR (TTM)30.31tn
  • Net income in IDR2.96tn
  • Incorporated1967
  • Employees13.13k
  • Location
    Kalbe Farma Tbk PTGedung KALBE Let.Jend Suprato Kav. 4JAKARTA PUSAT 10510IndonesiaIDN
  • Phone+62 2 142873888
  • Fax+62 214256326
  • Websitehttp://www.kalbe.co.id
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
IPCA Laboratories Ltd13.66tn1.07tn59.70tn16.17k55.62--33.544.3722.2522.25283.32--------4,444,876.00--11.95--15.3465.4759.178.4513.77--12.99--12.027.1113.72-46.6914.5129.3251.57
Tianjin Pharmcetl Da Ren Tang Grp Cp Ltd18.60tn2.17tn59.82tn4.91k21.923.34--3.221.281.2810.928.410.84663.283.411,725,886.009.688.7114.1212.3141.6940.2211.4310.091.48--0.153140.4219.427.7112.0512.60-1.1741.14
Biocon Ltd27.79tn2.28tn60.10tn3.41k26.34--10.482.1610.0310.03122.21--------42,877,050.00--4.31--5.9167.1761.3410.1910.87--1.66--8.4936.5422.03-28.644.4413.5024.57
Genscript Biotech Corp13.31tn-1.51tn62.39tn6.94k--2.83--4.69-0.3546-0.35463.115.130.2837.595.34946,863.30-11.97-18.34-18.27-26.1548.7854.68-42.30-64.914.65--0.1694--34.1729.4457.91------
GlaxoSmithKline Pharmaceuticals Limited6.30tn1.01tn62.71tn3.68k62.33--55.189.9631.2331.23195.53--------8,998,269.00--9.94--16.0160.3754.7115.9711.58--447.28--196.13-0.80252.3559.5811.62-35.7912.83
Kangmei Pharmaceutical Co Ltd10.95tn-4.28tn63.57tn6.37k--4.24--5.80-0.1415-0.14150.36210.49320.33141.452.97783,623.30-12.98-13.27-20.11-23.8110.67-41.71-39.18-71.370.8167-121.100.0446--0.6654-24.97-133.96---53.22--
Sichuan Kelun-Biotech Biophrmctcl Co Ltd3.38tn-1.26tn68.83tn1.42k--13.47--20.37-4.04-4.049.0811.51------1,178,606.00--------49.28---37.27--2.47-6.170.0251--91.62--6.81------
Kalbe Farma Tbk PT30.31tn2.96tn69.14tn13.13k23.173.3018.492.2863.6763.67651.66446.981.142.726.512,382,328,000.0011.2013.3714.3816.4138.0042.919.8611.902.18--0.046350.1210.187.476.247.07-6.778.73
Humanwell Healthcare Group Co Ltd53.23tn4.34tn69.30tn16.07k15.891.89--1.301.221.2215.0410.260.68144.112.841,509,763.007.653.4714.597.2144.4341.5911.225.791.2040.800.351722.328.717.6688.604.5412.420.00
Data as of Mar 28 2024. Currency figures normalised to Kalbe Farma Tbk PT's reporting currency: Indonesian Rupiah IDR

Institutional shareholders

12.12%Per cent of shares held by top holders
HolderShares% Held
RBC Global Asset Management (UK) Ltd.as of 31 Jan 2024940.48m2.01%
First Sentier Investors (Hong Kong) Ltd.as of 30 Nov 2023866.18m1.85%
The Vanguard Group, Inc.as of 07 Mar 2024725.25m1.55%
First Sentier Investors (UK) IM Ltd.as of 29 Feb 2024691.52m1.48%
Norges Bank Investment Managementas of 31 Dec 2023644.42m1.38%
BlackRock Fund Advisorsas of 07 Mar 2024548.06m1.17%
Invesco Advisers, Inc.as of 31 Jan 2024446.53m0.95%
PT Schroder Investment Management Indonesiaas of 31 Dec 2022333.49m0.71%
BlackRock Advisors (UK) Ltd.as of 06 Mar 2024259.79m0.55%
MFS International Singapore Pte. Ltd.as of 31 Jan 2024224.71m0.48%
More ▼
Data from 31 Dec 2022 - 29 Feb 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.